Fortrea completes divestiture of Endpoint Clinical, Fortrea Patient Access

Fortrea announced it has completed the divestiture of assets relating to its Enabling Services segment, namely its Endpoint Clinical and Fortrea Patient Access businesses, to Arsenal Capital Partners, a leading private equity firm specializing in building market-leading, technology-rich healthcare and industrial growth companies. “Endpoint and FPA are distinctly positioned to support the patient journey across clinical trials and through access to novel therapeutics after approval,” said Sam Osman, chief executive officer of Endpoint and FPA. “With Arsenal as our partner, I am confident that both our businesses and our teams will benefit from accelerated growth opportunities as well as investment and executive focus, resulting in enhanced capabilities and solutions for customers.”